PT1162999E - Vacina contra streptococcus pneumoniae - Google Patents
Vacina contra streptococcus pneumoniae Download PDFInfo
- Publication number
- PT1162999E PT1162999E PT00916983T PT00916983T PT1162999E PT 1162999 E PT1162999 E PT 1162999E PT 00916983 T PT00916983 T PT 00916983T PT 00916983 T PT00916983 T PT 00916983T PT 1162999 E PT1162999 E PT 1162999E
- Authority
- PT
- Portugal
- Prior art keywords
- protein
- polysaccharide
- vaccine
- mpl
- adjuvant
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims description 133
- 241000193998 Streptococcus pneumoniae Species 0.000 title claims description 45
- 229940031000 streptococcus pneumoniae Drugs 0.000 title claims description 45
- 229920001282 polysaccharide Polymers 0.000 claims description 258
- 239000005017 polysaccharide Substances 0.000 claims description 258
- 150000004676 glycans Chemical class 0.000 claims description 248
- 239000000203 mixture Substances 0.000 claims description 148
- 108090000623 proteins and genes Proteins 0.000 claims description 129
- 102000004169 proteins and genes Human genes 0.000 claims description 120
- 239000002671 adjuvant Substances 0.000 claims description 119
- 108091007433 antigens Proteins 0.000 claims description 108
- 102000036639 antigens Human genes 0.000 claims description 108
- 239000000427 antigen Substances 0.000 claims description 87
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims description 86
- 101710188053 Protein D Proteins 0.000 claims description 86
- 101710132893 Resolvase Proteins 0.000 claims description 86
- 230000002163 immunogen Effects 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 45
- 101710183389 Pneumolysin Proteins 0.000 claims description 43
- 230000004044 response Effects 0.000 claims description 27
- 241000606768 Haemophilus influenzae Species 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 206010035664 Pneumonia Diseases 0.000 claims description 17
- 229960000814 tetanus toxoid Drugs 0.000 claims description 16
- 206010033078 Otitis media Diseases 0.000 claims description 15
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 15
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 15
- 238000012217 deletion Methods 0.000 claims description 13
- 230000037430 deletion Effects 0.000 claims description 13
- 230000003308 immunostimulating effect Effects 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 9
- 108091034117 Oligonucleotide Proteins 0.000 claims description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 6
- 229930182490 saponin Natural products 0.000 claims description 6
- 150000007949 saponins Chemical class 0.000 claims description 6
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims description 5
- 101710099976 Photosystem I P700 chlorophyll a apoprotein A1 Proteins 0.000 claims description 5
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 4
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 claims description 4
- 239000000411 inducer Substances 0.000 claims description 4
- 239000007764 o/w emulsion Substances 0.000 claims description 4
- 239000003053 toxin Substances 0.000 claims description 4
- 231100000765 toxin Toxicity 0.000 claims description 4
- 108700012359 toxins Proteins 0.000 claims description 4
- 108060003552 hemocyanin Proteins 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229960001005 tuberculin Drugs 0.000 claims description 3
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 241000237988 Patellidae Species 0.000 claims description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 229960001438 immunostimulant agent Drugs 0.000 claims 3
- 239000003022 immunostimulating agent Substances 0.000 claims 3
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 114
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 56
- 241000699670 Mus sp. Species 0.000 description 40
- XWPMJTCUMKDEIW-UHFFFAOYSA-N 4-(dimethylamino)-2h-pyridine-1-carbonitrile Chemical compound CN(C)C1=CCN(C#N)C=C1 XWPMJTCUMKDEIW-UHFFFAOYSA-N 0.000 description 31
- 238000009472 formulation Methods 0.000 description 31
- 239000011780 sodium chloride Substances 0.000 description 31
- 230000003053 immunization Effects 0.000 description 29
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 27
- 229910052782 aluminium Inorganic materials 0.000 description 27
- 238000002649 immunization Methods 0.000 description 27
- 239000003981 vehicle Substances 0.000 description 25
- 108010060123 Conjugate Vaccines Proteins 0.000 description 23
- 229940031670 conjugate vaccine Drugs 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 230000005847 immunogenicity Effects 0.000 description 21
- 230000000890 antigenic effect Effects 0.000 description 20
- 238000009739 binding Methods 0.000 description 19
- 208000015181 infectious disease Diseases 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 18
- 230000004913 activation Effects 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 16
- 229940047650 haemophilus influenzae Drugs 0.000 description 16
- 230000028993 immune response Effects 0.000 description 16
- 210000004072 lung Anatomy 0.000 description 16
- 230000001662 opsonic effect Effects 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 230000001580 bacterial effect Effects 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 15
- 102000014914 Carrier Proteins Human genes 0.000 description 14
- 108010078791 Carrier Proteins Proteins 0.000 description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 241000588650 Neisseria meningitidis Species 0.000 description 13
- 238000001914 filtration Methods 0.000 description 13
- 210000000987 immune system Anatomy 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 230000005875 antibody response Effects 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 208000035109 Pneumococcal Infections Diseases 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 230000001976 improved effect Effects 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- 230000001681 protective effect Effects 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 230000021615 conjugation Effects 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000000855 fermentation Methods 0.000 description 8
- 230000004151 fermentation Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000002255 vaccination Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 7
- 230000002238 attenuated effect Effects 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 6
- 241000701959 Escherichia virus Lambda Species 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 229940001442 combination vaccine Drugs 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 210000003622 mature neutrocyte Anatomy 0.000 description 6
- 229940031937 polysaccharide vaccine Drugs 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 5
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 5
- 229940037003 alum Drugs 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 229960005323 phenoxyethanol Drugs 0.000 description 5
- 229940124733 pneumococcal vaccine Drugs 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 208000022218 streptococcal pneumonia Diseases 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 238000013518 transcription Methods 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- -1 type A Chemical class 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000012506 Sephacryl® Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 239000002158 endotoxin Substances 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 230000008588 hemolysis Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 230000001320 lysogenic effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108010021711 pertactin Proteins 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229940031960 pneumococcal polysaccharide vaccine Drugs 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 201000009906 Meningitis Diseases 0.000 description 3
- 241000588655 Moraxella catarrhalis Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091005461 Nucleic proteins Proteins 0.000 description 3
- 238000011795 OF1 mouse Methods 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 201000004283 Shwachman-Diamond syndrome Diseases 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 230000029662 T-helper 1 type immune response Effects 0.000 description 3
- 206010043376 Tetanus Diseases 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000021028 berry Nutrition 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate group Chemical group [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 206010013023 diphtheria Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000028996 humoral immune response Effects 0.000 description 3
- 230000006054 immunological memory Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000021633 leukocyte mediated immunity Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000029219 regulation of pH Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 3
- 230000001018 virulence Effects 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000031729 Bacteremia Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 201000007336 Cryptococcosis Diseases 0.000 description 2
- 241000221204 Cryptococcus neoformans Species 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 101000597577 Gluconacetobacter diazotrophicus (strain ATCC 49037 / DSM 5601 / CCUG 37298 / CIP 103539 / LMG 7603 / PAl5) Outer membrane protein Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- 201000005702 Pertussis Diseases 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- 229940124858 Streptococcus pneumoniae vaccine Drugs 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 108010031133 Transferrin-Binding Protein A Proteins 0.000 description 2
- 108010031127 Transferrin-Binding Protein B Proteins 0.000 description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 2
- 230000000240 adjuvant effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000007333 cyanation reaction Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000001667 episodic effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000005189 flocculation Methods 0.000 description 2
- 230000016615 flocculation Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical class O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 2
- 150000002632 lipids Chemical group 0.000 description 2
- 108010000138 lipopeptidophosphoglycan Proteins 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 239000006916 nutrient agar Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000010979 pH adjustment Methods 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 229960001973 pneumococcal vaccines Drugs 0.000 description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000006748 scratching Methods 0.000 description 2
- 230000002393 scratching effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229960001295 tocopherol Drugs 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 235000010384 tocopherol Nutrition 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 2
- 230000005951 type IV hypersensitivity Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 150000003751 zinc Chemical class 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PMTMAFAPLCGXGK-JMTMCXQRSA-N (15Z)-12-oxophyto-10,15-dienoic acid Chemical compound CC\C=C/C[C@H]1[C@@H](CCCCCCCC(O)=O)C=CC1=O PMTMAFAPLCGXGK-JMTMCXQRSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- UUKWKUSGGZNXGA-UHFFFAOYSA-N 3,5-dinitrobenzamide Chemical compound NC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 UUKWKUSGGZNXGA-UHFFFAOYSA-N 0.000 description 1
- 101710105077 Agglutinin-1 Proteins 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 101150036540 Copb1 gene Proteins 0.000 description 1
- 241000759568 Corixa Species 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 230000007064 DNA hydrolysis Effects 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 229940032024 DPT vaccine Drugs 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 101100402127 Escherichia coli (strain K12) moaA gene Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 238000000729 Fisher's exact test Methods 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 101001015673 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Glycerophosphodiester phosphodiesterase Proteins 0.000 description 1
- 101100406392 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) omp26 gene Proteins 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 241000588621 Moraxella Species 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 1
- QVLMCRFQGHWOPM-ZKWNWVNESA-N N-arachidonoyl vanillylamine Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCC1=CC=C(O)C(OC)=C1 QVLMCRFQGHWOPM-ZKWNWVNESA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- DZTHIGRZJZPRDV-UHFFFAOYSA-N Nalpha-Acetyltryptophan Natural products C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- PMTMAFAPLCGXGK-UHFFFAOYSA-N OPDA Natural products CCC=CCC1C(CCCCCCCC(O)=O)C=CC1=O PMTMAFAPLCGXGK-UHFFFAOYSA-N 0.000 description 1
- 101100028078 Oryza sativa subsp. japonica OPR1 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102100035181 Plastin-1 Human genes 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 229920001231 Polysaccharide peptide Polymers 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 description 1
- 101710110023 Putative adhesin Proteins 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108010055044 Tetanus Toxin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FHICGHSMIPIAPL-HDYAAECPSA-N [2-[3-[6-[3-[(5R,6aS,6bR,12aR)-10-[6-[2-[2-[4,5-dihydroxy-3-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]ethoxy]ethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-5-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carbonyl]peroxypropyl]-5-[[5-[8-[3,5-dihydroxy-4-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]octoxy]-3,4-dihydroxy-6-methyloxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]propoxymethyl]-5-hydroxy-3-[(6S)-6-hydroxy-2,6-dimethylocta-2,7-dienoyl]oxy-6-methyloxan-4-yl] (2E,6S)-6-hydroxy-2-(hydroxymethyl)-6-methylocta-2,7-dienoate Chemical compound C=C[C@@](C)(O)CCC=C(C)C(=O)OC1C(OC(=O)C(\CO)=C\CC[C@](C)(O)C=C)C(O)C(C)OC1COCCCC1C(O)C(O)C(OCC2C(C(O)C(OCCCCCCCCC3C(C(OC4C(C(O)C(O)CO4)O)C(O)CO3)O)C(C)O2)O)C(CCCOOC(=O)C23C(CC(C)(C)CC2)C=2[C@@]([C@]4(C)CCC5C(C)(C)C(OC6C(C(O)C(O)C(CCOCCC7C(C(O)C(O)CO7)OC7C(C(O)C(O)CO7)O)O6)O)CC[C@]5(C)C4CC=2)(C)C[C@H]3O)O1 FHICGHSMIPIAPL-HDYAAECPSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000001727 anti-capsular Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 108091016312 choline binding proteins Proteins 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000004643 cyanate ester Substances 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000033447 immunodeficiency 67 Diseases 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000022760 infectious otitis media Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 229940124731 meningococcal vaccine Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229940031346 monovalent vaccine Drugs 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 229940116191 n-acetyltryptophan Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 108010049148 plastin Proteins 0.000 description 1
- 229940031999 pneumococcal conjugate vaccine Drugs 0.000 description 1
- 229940033515 pneumovax 23 Drugs 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108010022457 polysaccharide peptide Proteins 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 229940070741 purified protein derivative of tuberculin Drugs 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 125000005630 sialyl group Chemical group 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940118376 tetanus toxin Drugs 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000029069 type 2 immune response Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9906437.0A GB9906437D0 (en) | 1999-03-19 | 1999-03-19 | Vaccine |
| GBGB9909077.1A GB9909077D0 (en) | 1999-04-20 | 1999-04-20 | Novel compositions |
| GBGB9909466.6A GB9909466D0 (en) | 1999-04-23 | 1999-04-23 | Vaccines |
| GBGB9916677.9A GB9916677D0 (en) | 1999-07-15 | 1999-07-15 | Vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1162999E true PT1162999E (pt) | 2007-02-28 |
Family
ID=27451884
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT00916983T PT1162999E (pt) | 1999-03-19 | 2000-03-17 | Vacina contra streptococcus pneumoniae |
| PT00912626T PT1163000E (pt) | 1999-03-19 | 2000-03-17 | Vacina contra antigénios de bactérias |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT00912626T PT1163000E (pt) | 1999-03-19 | 2000-03-17 | Vacina contra antigénios de bactérias |
Country Status (32)
Families Citing this family (290)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030157129A1 (en) * | 1995-06-23 | 2003-08-21 | Smithkline Beecham Biologicals S.A. | Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein |
| US7078042B2 (en) * | 1995-09-15 | 2006-07-18 | Uab Research Foundation | Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor |
| GB2324093A (en) | 1996-01-04 | 1998-10-14 | Rican Limited | Helicobacter pylori bacterioferritin |
| FR2763244B1 (fr) | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
| US20010016200A1 (en) | 1998-04-23 | 2001-08-23 | Briles David E. | Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor |
| DK1733735T3 (en) | 1998-05-22 | 2017-06-19 | Ottawa Hospital Res Inst | Methods and products for the induction of mucosal immunity |
| US6797275B1 (en) * | 1998-12-04 | 2004-09-28 | The United States Of America As Represented By The Department Of Health And Human Services | Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine |
| JP2002539273A (ja) | 1999-03-19 | 2002-11-19 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
| GB9925559D0 (en) * | 1999-10-28 | 1999-12-29 | Smithkline Beecham Biolog | Novel method |
| GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| GB0022742D0 (en) * | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| ATE439372T1 (de) | 2000-10-27 | 2009-08-15 | Novartis Vaccines & Diagnostic | Nukleinsäuren und proteine von gruppen a und b- streptokokken |
| GB2370770B (en) * | 2001-01-03 | 2005-06-01 | Simon Connolly | Uses of Streptococcus Vaccines |
| US7082569B2 (en) | 2001-01-17 | 2006-07-25 | Outlooksoft Corporation | Systems and methods providing dynamic spreadsheet functionality |
| PT2332581E (pt) | 2001-01-23 | 2015-10-16 | Sanofi Pasteur Inc | Vacina meningocócica tri- ou tetravalente de conjugados de polissacárido e crm-197 |
| DE60239594D1 (de) | 2001-02-23 | 2011-05-12 | Glaxosmithkline Biolog Sa | Influenza vakzinzusammensetzungen zur intradermaler verabreichung |
| GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| US8481043B2 (en) | 2001-06-22 | 2013-07-09 | Cpex Pharmaceuticals, Inc. | Nasal immunization |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| EP2168596B1 (en) | 2001-12-12 | 2012-05-23 | Novartis Vaccines and Diagnostics S.r.l. | Immunisation against chlamydia trachomatis |
| GB0130215D0 (en) * | 2001-12-18 | 2002-02-06 | Glaxosmithkline Biolog Sa | Vaccine |
| US7501134B2 (en) | 2002-02-20 | 2009-03-10 | Novartis Vaccines And Diagnostics, Inc. | Microparticles with adsorbed polypeptide-containing molecules |
| DE60328481D1 (de) * | 2002-05-14 | 2009-09-03 | Novartis Vaccines & Diagnostic | Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthält |
| CN1816350B (zh) * | 2002-05-14 | 2010-11-10 | 莱顿大学 | 带有几丁聚糖佐剂和/或脑膜炎抗原的粘膜疫苗 |
| GB0302218D0 (en) | 2003-01-30 | 2003-03-05 | Chiron Sri | Vaccine formulation & Mucosal delivery |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| CN1809380B (zh) | 2002-10-11 | 2010-05-12 | 启龙有限公司 | 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗 |
| EP2314603A3 (en) * | 2002-10-15 | 2011-05-18 | Intercell AG | Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and futher uses thereof |
| MXPA05004528A (es) | 2002-11-01 | 2005-07-26 | Glaxosmithkline Biolog Sa | Composicion inmunogenica. |
| MXPA05005045A (es) | 2002-11-12 | 2005-07-01 | Brigham & Womens Hospital | Vacuna de polisacarido para infecciones estafilococicas. |
| WO2004046177A2 (en) | 2002-11-15 | 2004-06-03 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
| GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| JP2006512927A (ja) | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ，インコーポレイテッド | ５’ｃｐｇ核酸およびその使用方法 |
| AU2003299994A1 (en) | 2002-12-27 | 2004-07-29 | Chiron Corporation | Immunogenic compositions containing phospholpid |
| FR2850106B1 (fr) * | 2003-01-17 | 2005-02-25 | Aventis Pasteur | Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5 |
| ES2461350T3 (es) * | 2003-01-30 | 2014-05-19 | Novartis Ag | Vacunas inyectables contra múltiples serogrupos de meningococos |
| WO2004080490A2 (en) * | 2003-03-07 | 2004-09-23 | Wyeth Holdings Corporation | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| PT1601689E (pt) * | 2003-03-13 | 2008-01-04 | Glaxosmithkline Biolog Sa | Processo de purificação para citolisina bacteriana |
| EP2258365B1 (en) | 2003-03-28 | 2013-05-29 | Novartis Vaccines and Diagnostics, Inc. | Use of organic compounds for immunopotentiation |
| JP5557415B2 (ja) | 2003-06-02 | 2014-07-23 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物 |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| NZ546430A (en) * | 2003-10-02 | 2009-04-30 | Novartis Vaccines & Diagnostic | Liquid vaccines for multiple meningococcal serogroups |
| GB0406013D0 (en) | 2004-03-17 | 2004-04-21 | Chiron Srl | Analysis of saccharide vaccines without interference |
| GB0500787D0 (en) | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
| GB0409745D0 (en) | 2004-04-30 | 2004-06-09 | Chiron Srl | Compositions including unconjugated carrier proteins |
| US9402915B2 (en) | 2004-04-30 | 2016-08-02 | Glaxosmithkline Biologicals Sa | Integration of meningococcal conjugate vaccination |
| US7444197B2 (en) * | 2004-05-06 | 2008-10-28 | Smp Logic Systems Llc | Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes |
| GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| GB0411387D0 (en) | 2004-05-21 | 2004-06-23 | Chiron Srl | Analysis of saccharide length |
| GB0413868D0 (en) | 2004-06-21 | 2004-07-21 | Chiron Srl | Dimensional anlaysis of saccharide conjugates |
| WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
| CA2571421A1 (en) | 2004-06-24 | 2006-01-05 | Nicholas Valiante | Compounds for immunopotentiation |
| US20060165716A1 (en) | 2004-07-29 | 2006-07-27 | Telford John L | Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| LT2682126T (lt) | 2005-01-27 | 2017-02-27 | Children`s Hospital & Research Center at Oakland | Gna1870 pagrindu gaminamos pūslelių pavidalo vakcinos, skirtos plataus spektro apsaugai nuo neisseria meningitidis sukeltų ligų |
| GB0502095D0 (en) | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
| SI2351772T1 (sl) | 2005-02-18 | 2016-11-30 | Glaxosmithkline Biologicals Sa | Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso |
| JP2008530245A (ja) | 2005-02-18 | 2008-08-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 尿路病原性菌株由来の抗原 |
| GB0505518D0 (en) * | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
| US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| EP2425853A1 (en) * | 2005-04-08 | 2012-03-07 | Wyeth LLC | Multivalent Pneumococcal Polysaccharide-Protein Conjugate Composition |
| US7709001B2 (en) * | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| US20070184072A1 (en) * | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| BRPI0610297A2 (pt) | 2005-04-18 | 2010-06-08 | Novartis Vaccines & Diagnostic | expressão de antìgeno de superfìcie de vìrus da hepatite b para a preparação de vacina |
| LT2351578T (lt) | 2005-06-27 | 2017-04-10 | Glaxosmithkline Biologicals S.A. | Vakcinų gavimo būdas |
| EP2308504A3 (en) | 2005-09-01 | 2011-11-30 | Novartis Vaccines and Diagnostics GmbH | Multiple vaccines including serogroup C meningococcus |
| GB0522765D0 (en) | 2005-11-08 | 2005-12-14 | Chiron Srl | Combination vaccine manufacture |
| AU2006335256B2 (en) | 2005-11-22 | 2012-10-18 | Novartis Vaccines And Diagnostics, Inc. | Norovirus and sapovirus antigens |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| BRPI0620460B8 (pt) * | 2005-12-22 | 2021-05-25 | Glaxosmithkline Biologicals Sa | uso de composição imunogênica para bebês, e, processo para produzir uma vacina |
| EP1973933B1 (en) * | 2006-01-17 | 2020-06-24 | Forsgren, Arne | A NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZAE PROTEIN (PROTEIN E; pE) |
| CN101024079B (zh) * | 2006-02-17 | 2012-02-01 | 福州昌晖生物工程有限公司 | 肺炎链球菌多糖-外膜蛋白结合疫苗及制备方法 |
| CN101405028B (zh) * | 2006-03-17 | 2015-08-19 | 美国政府健康及人类服务部 | 制备复合的多价免疫原性结合物的方法 |
| ES2383209T3 (es) | 2006-03-22 | 2012-06-19 | Novartis Ag | Regímenes para la inmunización con conjugados meningococicos |
| US10828361B2 (en) | 2006-03-22 | 2020-11-10 | Glaxosmithkline Biologicals Sa | Regimens for immunisation with meningococcal conjugates |
| GB0605757D0 (en) | 2006-03-22 | 2006-05-03 | Chiron Srl | Separation of conjugated and unconjugated components |
| WO2007109813A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| PE20080774A1 (es) * | 2006-03-30 | 2008-08-08 | Glaxosmithkline Biolog Sa | Composicion inmunogenica que comprende pnag de estafilococos conjugada con una proteina portadora y polisacarido u oligosacarido capsular de s. aureus |
| MY148405A (en) * | 2006-03-30 | 2013-04-30 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| US8808707B1 (en) | 2006-05-08 | 2014-08-19 | Wyeth Llc | Pneumococcal dosing regimen |
| ATE522541T1 (de) * | 2006-06-09 | 2011-09-15 | Novartis Ag | Bakterielle adhäsine konformere |
| GB0612854D0 (en) | 2006-06-28 | 2006-08-09 | Novartis Ag | Saccharide analysis |
| EP2586790A3 (en) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
| KR101467002B1 (ko) * | 2006-10-10 | 2014-12-01 | 와이어쓰 엘엘씨 | 스트렙토코쿠스 뉴모니애 제3형 다당류의 정제 방법 |
| GB0700136D0 (en) | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| BRPI0813644B8 (pt) * | 2007-06-26 | 2021-05-25 | Glaxosmithkline Biologicals Sa | composição imunogênica, vacina, processo para fabricar a mesma, e, uso da composição imunogênica ou vacina |
| GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| GB0714963D0 (en) | 2007-08-01 | 2007-09-12 | Novartis Ag | Compositions comprising antigens |
| CA2699513C (en) | 2007-09-12 | 2018-03-13 | Novartis Ag | Gas57 mutant antigens and gas57 antibodies |
| BR122016015627A2 (pt) | 2007-10-19 | 2018-10-30 | Novartis Ag | kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica |
| EP2217250A4 (en) | 2007-11-09 | 2011-01-05 | California Inst Of Techn | IMMUNOMODULATING COMPOUNDS AND RELEVANT COMPOSITIONS AND METHODS |
| EP2244695A1 (en) | 2007-12-07 | 2010-11-03 | Novartis AG | Compositions for inducing immune responses |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| BRPI0821240B8 (pt) | 2007-12-21 | 2022-10-04 | Novartis Ag | formas mutantes de estreptolisina o |
| WO2009094730A1 (en) * | 2008-02-01 | 2009-08-06 | Newcastle Innovation Limited | Vaccine compositions |
| EP2886551A3 (en) | 2008-02-21 | 2015-09-23 | Novartis AG | Meningococcal fhbp polypeptides |
| EP2631245A1 (en) | 2008-03-10 | 2013-08-28 | Children's Hospital & Research Center at Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
| NZ591103A (en) | 2008-07-21 | 2013-02-22 | Brigham & Womens Hospital | Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides |
| CN102264444B (zh) | 2008-10-27 | 2015-08-05 | 诺华股份有限公司 | 纯化方法 |
| MX337723B (es) | 2008-12-09 | 2016-03-15 | Pfizer Vaccines Llc | Vacuna de peptido ch3 de ige. |
| GB0822633D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Formulation |
| GB0822634D0 (en) | 2008-12-11 | 2009-01-21 | Novartis Ag | Meningitis vaccines |
| WO2010070453A2 (en) | 2008-12-17 | 2010-06-24 | Novartis Ag | Meningococcal vaccines including hemoglobin receptor |
| CA2748788C (en) | 2009-01-05 | 2021-02-09 | Epitogenesis Inc. | The use of a composition comprising mustard oil, catechin, and vitamin a for modulating an immune response |
| CN102481349B (zh) | 2009-01-12 | 2014-10-15 | 诺华股份有限公司 | 抗革兰氏阳性细菌疫苗中的Cna_B结构域 |
| PL2411048T3 (pl) | 2009-03-24 | 2020-11-16 | Glaxosmithkline Biologicals Sa | Adjuwantowe meningokokowe białko wiążące czynnik h |
| US20120064103A1 (en) | 2009-03-24 | 2012-03-15 | Novartis Ag | Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates |
| NZ612315A (en) | 2009-04-14 | 2014-10-31 | Novartis Ag | Compositions for immunising against staphylococcus aureus |
| WO2010132833A1 (en) | 2009-05-14 | 2010-11-18 | The Regents Of The University Of Michigan | Streptococcus vaccine compositions and methods of using the same |
| CN102481352A (zh) | 2009-06-22 | 2012-05-30 | 惠氏有限责任公司 | 金黄色葡萄球菌抗原的免疫原性组合物 |
| SA114350400B1 (ar) | 2009-06-22 | 2016-05-26 | ويث ال ال سي | تركيبات وطرق لتحضير تركيبات مولدة للمناعة لمقترن بولي سكاريد كبسولي للنمط المصلي 5 و 8 من المكورات العنقودية الذهبية |
| US8647621B2 (en) | 2009-07-27 | 2014-02-11 | Fina Biosolutions, Llc | Method of producing protein-carbohydrate vaccines reduced in free carbohydrate |
| CA2768346A1 (en) | 2009-07-30 | 2011-02-03 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
| JP2013502918A (ja) | 2009-08-27 | 2013-01-31 | ノバルティス アーゲー | 髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド |
| DK2473605T3 (en) | 2009-09-03 | 2018-05-28 | Pfizer Vaccines Llc | PCSK9-VACCINE |
| WO2011030218A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Combination vaccines against respiratory tract diseases |
| BR112012010531A2 (pt) | 2009-10-27 | 2019-09-24 | Novartis Ag | "polipeptídeos de modificação meningocócica fhbp" |
| PL2493498T3 (pl) | 2009-10-30 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8 |
| GB0919690D0 (en) | 2009-11-10 | 2009-12-23 | Guy S And St Thomas S Nhs Foun | compositions for immunising against staphylococcus aureus |
| CA2836140C (en) | 2009-12-17 | 2016-06-21 | Fina Biosolutions, Llc | Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines |
| SG181628A1 (en) | 2009-12-22 | 2012-07-30 | Celldex Therapeutics Inc | Vaccine compositions |
| GB201003333D0 (en) | 2010-02-26 | 2010-04-14 | Novartis Ag | Immunogenic proteins and compositions |
| GB201003922D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Conjugation process |
| WO2011126863A1 (en) | 2010-03-30 | 2011-10-13 | Children's Hospital & Research Center Oakland | Factor h binding proteins (fhbp) with altered properties and methods of use thereof |
| GB201005625D0 (en) | 2010-04-01 | 2010-05-19 | Novartis Ag | Immunogenic proteins and compositions |
| HUE040658T2 (hu) | 2010-04-07 | 2019-03-28 | California Inst Of Techn | Vivõanyag vegyület mukózus membránhoz juttatásához és kapcsolódó készítmények, eljárások és rendszerek |
| US20110287048A1 (en) * | 2010-05-20 | 2011-11-24 | Round June L | Antigen Specific Tregs and related compositions, methods and systems |
| CN102933267B (zh) | 2010-05-28 | 2015-05-27 | 泰特里斯在线公司 | 交互式混合异步计算机游戏基础结构 |
| PT3170508T (pt) * | 2010-06-04 | 2020-01-16 | Wyeth Llc | Formulações de vacinas |
| EP2942061A3 (en) | 2010-06-07 | 2016-01-13 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
| US8895017B2 (en) | 2010-06-07 | 2014-11-25 | Pfizer Inc. | HER-2 peptides and vaccines |
| CA2803239A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
| GB201101665D0 (en) | 2011-01-31 | 2011-03-16 | Novartis Ag | Immunogenic compositions |
| WO2012085668A2 (en) | 2010-12-24 | 2012-06-28 | Novartis Ag | Compounds |
| WO2012103421A1 (en) | 2011-01-27 | 2012-08-02 | Novartis Ag | Adjuvant nanoemulsions with crystallisation inhibitors |
| US20140112950A1 (en) | 2011-03-02 | 2014-04-24 | Manmohan Singh | Combination vaccines with lower doses of antigen and/or adjuvant |
| GB201103836D0 (en) | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
| US10357568B2 (en) | 2011-03-24 | 2019-07-23 | Glaxosmithkline Biologicals S.A. | Adjuvant nanoemulsions with phospholipids |
| EP2511295A1 (en) | 2011-04-15 | 2012-10-17 | Institut National De La Sante Et De La Recherche Medicale | Compositions for preventing and/or treating an infection by an HIV-1 virus |
| US20130203980A1 (en) | 2011-05-06 | 2013-08-08 | Petr Gennadievich Aparin | Exopolysaccharide of shigella sonnei bacteria, method for producing same, vaccine and pharmaceutical composition containing same |
| US10561720B2 (en) | 2011-06-24 | 2020-02-18 | EpitoGenesis, Inc. | Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators |
| EP2729178A1 (en) | 2011-07-08 | 2014-05-14 | Novartis AG | Tyrosine ligation process |
| GB201114923D0 (en) | 2011-08-30 | 2011-10-12 | Novartis Ag | Immunogenic proteins and compositions |
| EP2755683B1 (en) | 2011-09-14 | 2019-04-03 | GlaxoSmithKline Biologicals SA | Methods for making saccharide-protein glycoconjugates |
| US20140235667A1 (en) | 2011-09-22 | 2014-08-21 | Merck Sharp & Dohme Corp. | Imidazopyridyl compounds as aldosterone synthase inhibitors |
| WO2013068949A1 (en) | 2011-11-07 | 2013-05-16 | Novartis Ag | Carrier molecule comprising a spr0096 and a spr2021 antigen |
| DE102011122891B4 (de) | 2011-11-11 | 2014-12-24 | Novartis Ag | Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen |
| DE102011118371B4 (de) | 2011-11-11 | 2014-02-13 | Novartis Ag | Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung |
| GB2495341B (en) | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
| EP2592137A1 (en) | 2011-11-11 | 2013-05-15 | Novartis AG | Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use |
| EP2788022B1 (en) | 2011-12-08 | 2018-10-31 | GlaxoSmithKline Biologicals SA | Clostridium difficile toxin-based vaccine |
| GB201121301D0 (en) | 2011-12-12 | 2012-01-25 | Novartis Ag | Method |
| AU2011384634A1 (en) | 2011-12-29 | 2014-06-19 | Novartis Ag | Adjuvanted combinations of meningococcal factor H binding proteins |
| WO2013124473A1 (en) | 2012-02-24 | 2013-08-29 | Novartis Ag | Pilus proteins and compositions |
| CN104519910B (zh) | 2012-03-07 | 2017-05-03 | 诺华股份有限公司 | 肺炎链球菌抗原的含佐剂制剂 |
| JP2015509963A (ja) | 2012-03-08 | 2015-04-02 | ノバルティス アーゲー | Ｔｌｒ４アゴニストを含む混合ワクチン |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| US10279026B2 (en) | 2012-04-26 | 2019-05-07 | Glaxosmithkline Biologicals Sa | Antigens and antigen combinations |
| CN108671228A (zh) | 2012-04-26 | 2018-10-19 | 诺华股份有限公司 | 抗原和抗原组合 |
| RU2737765C2 (ru) | 2012-05-04 | 2020-12-02 | Пфайзер Инк. | Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин |
| RU2014151567A (ru) | 2012-05-22 | 2016-07-10 | Новартис Аг | Конъюгат менингококка серогруппы х |
| KR102057217B1 (ko) * | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| EP2892553A1 (en) | 2012-09-06 | 2015-07-15 | Novartis AG | Combination vaccines with serogroup b meningococcus and d/t/p |
| AR092896A1 (es) | 2012-10-03 | 2015-05-06 | Novartis Ag | Composiciones inmunogenicas |
| CA2886938A1 (en) | 2012-10-12 | 2014-04-17 | Glaxosmithkline Biologicals S.A. | Non-cross-linked acellular pertussis antigens for use in combination vaccines |
| US20140193451A1 (en) * | 2012-10-17 | 2014-07-10 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| MX2015005002A (es) * | 2012-10-17 | 2015-07-17 | Glaxosmithkline Biolog Sa | Composicion inmunogenica. |
| KR20140075201A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| KR20140075196A (ko) | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| TR201807340T4 (tr) | 2013-02-01 | 2018-06-21 | Glaxosmithkline Biologicals Sa | Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi. |
| WO2014182966A1 (en) | 2013-05-10 | 2014-11-13 | California Institute Of Technology | Probiotic prevention and treatment of colon cancer |
| EP2996718B1 (en) | 2013-05-15 | 2020-01-15 | The Governors of the University of Alberta | E1e2 hcv vaccines and methods of use |
| CN103386126B (zh) * | 2013-06-25 | 2015-06-17 | 北京科兴生物制品有限公司 | 一种含肠道病毒抗原的多价免疫原性组合物 |
| RU2662968C2 (ru) | 2013-09-08 | 2018-07-31 | Пфайзер Инк. | Иммуногенная композиция против neisseria meningitidis (варианты) |
| WO2015095868A1 (en) * | 2013-12-20 | 2015-06-25 | Wake Forest University Health Sciences | Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines |
| US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| PT3096785T (pt) | 2014-01-21 | 2020-10-13 | Pfizer | Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas |
| SI3096783T1 (sl) * | 2014-01-21 | 2021-09-30 | Pfizer Inc. | Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati |
| WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
| CA2940447C (en) | 2014-02-28 | 2023-07-11 | Glaxosmithkline Biologicals Sa | Modified meningococcal fhbp polypeptides |
| EP2921856B1 (en) * | 2014-03-18 | 2016-09-14 | Serum Institute Of India Private Limited | A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines |
| CN104829711B (zh) * | 2014-04-08 | 2018-04-03 | 北京天成新脉生物技术有限公司 | 脑膜炎球菌荚膜多糖单克隆抗体及其应用 |
| CN119613509A (zh) | 2014-07-23 | 2025-03-14 | 奥克兰儿童医院及研究中心 | 因子h结合蛋白变体及其使用方法 |
| US9815886B2 (en) | 2014-10-28 | 2017-11-14 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| EP3034516A1 (en) | 2014-12-19 | 2016-06-22 | Novartis AG | Purification of streptococcal capsular polysaccharide |
| EP3244917B1 (en) | 2015-01-15 | 2023-04-19 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| CN104548090B (zh) * | 2015-01-27 | 2016-11-30 | 中国科学院过程工程研究所 | 一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法 |
| WO2016184963A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| US11331335B2 (en) | 2015-06-10 | 2022-05-17 | California Institute Of Technology | Sepsis treatment and related compositions methods and systems |
| EP3109255A1 (en) | 2015-06-26 | 2016-12-28 | Institut National De La Recherche Agronomique | Immunogenic composition |
| EP3319988A1 (en) | 2015-07-07 | 2018-05-16 | Affiris AG | Vaccines for the treatment and prevention of ige mediated diseases |
| KR102225282B1 (ko) | 2015-07-21 | 2021-03-10 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
| EP4480544A3 (en) | 2015-08-25 | 2025-03-26 | Babita Agrawal | Immunomodulatory compositions andmethods of use thereof |
| CA3000313A1 (en) | 2015-10-08 | 2017-04-13 | The Governors Of The University Of Alberta | Hepatitis c virus e1/e2 heterodimers and methods of producing same |
| GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
| CA3005524C (en) | 2015-11-20 | 2023-10-10 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| CN108770343A (zh) | 2015-12-04 | 2018-11-06 | 达纳－法伯癌症研究所公司 | 用于治疗癌症的使用MICA/Bα3结构域的疫苗接种 |
| WO2017117539A1 (en) | 2015-12-30 | 2017-07-06 | Northwestern University | Cell-free glycoprotein synthesis (cfgps) in prokaryotic cell lysates enriched with components for glycosylation |
| ES2811523T3 (es) | 2016-01-19 | 2021-03-12 | Pfizer | Vacunas contra el cáncer |
| EP3439704A1 (en) | 2016-04-05 | 2019-02-13 | GSK Vaccines S.r.l. | Immunogenic compositions |
| US11191822B2 (en) * | 2016-06-22 | 2021-12-07 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
| US10829795B2 (en) | 2016-07-14 | 2020-11-10 | Northwestern University | Method for rapid in vitro synthesis of glycoproteins via recombinant production of N-glycosylated proteins in prokaryotic cell lysates |
| TWI770044B (zh) | 2016-08-05 | 2022-07-11 | 南韓商Ｓｋ生物科技股份有限公司 | 多價肺炎球菌多醣-蛋白質共軛物組成物(一) |
| SG11201900794PA (en) | 2016-08-05 | 2019-02-27 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
| WO2018042015A1 (en) | 2016-09-02 | 2018-03-08 | Glaxosmithkline Biologicals Sa | Vaccines for neisseria gonorrhoeae |
| IL302345B2 (en) | 2016-10-07 | 2024-12-01 | Enterome S A | Immunogenic compounds for cancer therapy |
| CN110022894B (zh) | 2016-10-07 | 2024-01-19 | 恩特罗姆公司 | 用于癌症疗法的免疫原性化合物 |
| BE1025162B9 (fr) | 2016-12-06 | 2019-01-07 | Glaxosmithkline Biologicals Sa | Procede de purification pour les polysaccharides capsulaires |
| MX392525B (es) | 2017-01-20 | 2025-03-12 | Pfizer | Composiciones inmunogenicas para su uso en vacunas neumococicas |
| US10183070B2 (en) | 2017-01-31 | 2019-01-22 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
| WO2018169303A1 (ko) * | 2017-03-15 | 2018-09-20 | 주식회사 엘지화학 | 다가 폐렴구균 백신 조성물 |
| WO2018178265A1 (en) | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
| US11167022B2 (en) | 2017-03-31 | 2021-11-09 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| KR20240018698A (ko) | 2017-06-10 | 2024-02-13 | 인벤트프라이즈 인크. | 면역원성과 항원항체 결합성이 개선된 2가 또는 다가 접합체 다당류를 가진 다가 접합체 백신 |
| GB201711635D0 (en) | 2017-07-19 | 2017-08-30 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| CN110996994A (zh) | 2017-08-14 | 2020-04-10 | 葛兰素史密丝克莱恩生物有限公司 | 加强免疫应答的方法 |
| EP3691677A4 (en) | 2017-10-04 | 2021-07-07 | Pogona, Llc | COMPOSITIONS OF SACCHARIDE-POLYPEPTIDE CONJUGATES AND THEIR METHODS OF USE |
| BR112020011414B8 (pt) | 2017-12-06 | 2023-01-31 | Merck Sharp & Dohme | Composições imunogênicas multivalentes compreendendo conjugados de proteína carreadora e polissacarídeo de s. pneumoniae |
| BR112020014978A2 (pt) | 2018-02-05 | 2020-12-22 | Sanofi Pasteur, Inc. | Composição de conjugado polissacarídeo-proteína pneumocócico multivalente |
| KR20230008923A (ko) | 2018-02-05 | 2023-01-16 | 사노피 파스퇴르 인코포레이티드 | 다가 폐렴구균성 다당류-단백질 접합체 조성물 |
| US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
| DK3773689T5 (da) | 2018-04-11 | 2024-08-19 | Enterome S A | Antigene peptider til forebyggelse og behandling af kræft |
| WO2019197563A2 (en) | 2018-04-11 | 2019-10-17 | Enterome S.A. | Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation |
| EP3782642A4 (en) | 2018-04-18 | 2022-04-13 | SK Bioscience Co., Ltd. | CAPSULE POLYSACCHARIDES FROM STREPTOCOCCUS PNEUMONIAE AND CONJUGATES THEREOF |
| US12018134B2 (en) | 2018-07-19 | 2024-06-25 | Glaxosmithkline Biological Sa | Processes for preparing dried polysaccharides |
| EP3833382A1 (en) | 2018-08-07 | 2021-06-16 | GlaxoSmithKline Biologicals S.A. | Processes and vaccines |
| US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| JP7585203B2 (ja) | 2018-12-12 | 2024-11-18 | ファイザー・インク | 免疫原性多重ヘテロ抗原多糖－タンパク質コンジュゲートおよびその使用 |
| US20220054632A1 (en) | 2018-12-12 | 2022-02-24 | Glaxosmithkline Biologicals Sa | Modified carrier proteins for o-linked glycosylation |
| EP3897705A2 (en) | 2018-12-19 | 2021-10-27 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| WO2020146814A1 (en) * | 2019-01-11 | 2020-07-16 | Northwestern University | Bioconjugate vaccines' synthesis in prokaryotic cell lysates |
| US12397014B2 (en) | 2019-02-05 | 2025-08-26 | The Brigham And Women's Hospital, Inc. | Polysaccharide compositions for use in treating filariasis |
| EP3923982A1 (en) | 2019-02-11 | 2021-12-22 | Pfizer Inc. | Neisseria meningitidiscompositions and methods thereof |
| JP7239509B6 (ja) | 2019-02-22 | 2023-03-28 | ファイザー・インク | 細菌多糖類を精製するための方法 |
| CA3136278A1 (en) | 2019-04-10 | 2020-10-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
| WO2020212461A1 (en) | 2019-04-18 | 2020-10-22 | Glaxosmithkline Biologicals Sa | Antigen binding proteins and assays |
| WO2020229964A1 (en) | 2019-05-10 | 2020-11-19 | Glaxosmithkline Biologicals Sa | Conjugate production |
| CA3148928A1 (en) | 2019-08-05 | 2021-02-11 | Glaxosmithkline Biologicals Sa | Process for preparing a composition comprising a protein d polypeptide |
| EP4010014A1 (en) | 2019-08-05 | 2022-06-15 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| EP4034157A1 (en) | 2019-09-27 | 2022-08-03 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| WO2021074389A1 (en) | 2019-10-16 | 2021-04-22 | Enterome S.A. | Immunogenic compounds for treatment of adrenal cancer |
| MX2022005252A (es) | 2019-11-01 | 2022-06-08 | Pfizer | Composiciones de escherichia coli y metodos de las mismas. |
| LT4021487T (lt) | 2019-11-15 | 2024-02-12 | Enterome S.A. | Antigeniniai peptidai, skirti b-ląstelių piktybinių navikų prevencijai ir gydymui |
| BR112022008761A2 (pt) | 2019-11-22 | 2022-07-26 | Glaxosmithkline Biologicals Sa | Dosagem e administração de uma vacina de glicoconjugado de sacarídeo |
| WO2021138495A1 (en) * | 2019-12-30 | 2021-07-08 | Fraunhofer Usa, Inc. | Particles for multi-dose delivery |
| MX2022010355A (es) | 2020-02-21 | 2022-09-21 | Pfizer | Purificacion de sacaridos. |
| MX2022010350A (es) | 2020-02-23 | 2022-09-19 | Pfizer | Composiciones de esquerichia coli y sus metodos. |
| CN111588847B (zh) * | 2020-05-18 | 2023-05-26 | 广州中医药大学(广州中医药研究院) | 一种含有单磷酸化的脂质a与糖抗原的缀合物及其制备方法和应用 |
| US20230250142A1 (en) | 2020-06-12 | 2023-08-10 | Glaxosmithkline Biologicals Sa | Dock tag system |
| EP4192499A4 (en) | 2020-08-10 | 2024-09-25 | Inventprise, Inc. | Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f |
| EP4237428A2 (en) | 2020-10-27 | 2023-09-06 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| US12138302B2 (en) | 2020-10-27 | 2024-11-12 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
| CA3200602A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
| US20230405137A1 (en) | 2020-11-10 | 2023-12-21 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| US12357681B2 (en) | 2020-12-23 | 2025-07-15 | Pfizer Inc. | E. coli FimH mutants and uses thereof |
| CA3211240A1 (en) | 2021-02-19 | 2022-08-25 | Sanofi Pasteur Inc. | Meningococcal b recombinant vaccine |
| US20240148849A1 (en) | 2021-02-22 | 2024-05-09 | Glaxosmithkline Biologicals Sa | Immunogenic composition, use and methods |
| EP4070814A1 (en) | 2021-04-07 | 2022-10-12 | Lama France | Sars-cov-2 polypeptides and uses thereof |
| CA3221075A1 (en) | 2021-05-28 | 2022-12-01 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| KR20230175284A (ko) | 2021-05-28 | 2023-12-29 | 화이자 인코포레이티드 | 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도 |
| AU2022391752A1 (en) | 2021-11-18 | 2024-06-13 | Matrivax, Inc. | Immunogenic fusion protein compositions and methods of use thereof |
| WO2023135515A1 (en) | 2022-01-13 | 2023-07-20 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| US20250163484A1 (en) | 2022-02-25 | 2025-05-22 | Pfizer Inc. | Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides |
| CN119522232A (zh) | 2022-03-31 | 2025-02-25 | 恩特姆生物科学公司 | 用于预防和治疗癌症的抗原肽 |
| IL316477A (en) | 2022-05-11 | 2024-12-01 | Pfizer | Process for producing vaccine formulations with preservatives |
| WO2024110827A1 (en) | 2022-11-21 | 2024-05-30 | Pfizer Inc. | Methods for preparing conjugated capsular saccharide antigens and uses thereof |
| IL321062A (en) | 2022-11-22 | 2025-07-01 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| KR20250113501A (ko) | 2022-12-01 | 2025-07-25 | 화이자 인코포레이티드 | 폐렴구균 접합체 백신 제형 |
| WO2024166008A1 (en) | 2023-02-10 | 2024-08-15 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| CN121038808A (zh) | 2023-03-30 | 2025-11-28 | 辉瑞公司 | 包含缀合的荚膜糖抗原的免疫原性组合物及其用途 |
| PE20252779A1 (es) | 2023-04-14 | 2025-12-22 | Pfizer | Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y usos de estos |
| WO2024224266A1 (en) | 2023-04-24 | 2024-10-31 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| WO2025109417A1 (en) | 2023-11-21 | 2025-05-30 | Panacea Biotec Limited | Immunogenic composition of haemophilus influenzae conjugated to protein d |
| WO2025133971A1 (en) | 2023-12-23 | 2025-06-26 | Pfizer Inc. | Improved methods for producing bacterial capsular saccharide glycoconjugates |
| WO2025186705A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
| TW202602467A (zh) | 2024-03-11 | 2026-01-16 | 美商輝瑞股份有限公司 | 包含經共軛之大腸桿菌糖的免疫原性組成物及其用途 |
| WO2025219904A1 (en) | 2024-04-19 | 2025-10-23 | Pfizer Inc. | Improved methods for producing glycoconjugates by reductive amination in aprotic solvent |
| CN120404993B (zh) * | 2025-07-03 | 2025-10-03 | 成都迈科康生物科技有限公司 | 一种检测样本中mpl的方法及其相关应用 |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
| IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
| BE889979A (fr) | 1981-08-14 | 1982-02-15 | Smith Kline Rit | Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation |
| US5360897A (en) * | 1981-08-31 | 1994-11-01 | The University Of Rochester | Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad |
| US4761283A (en) * | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
| US4882317A (en) * | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
| US5173294A (en) | 1986-11-18 | 1992-12-22 | Research Foundation Of State University Of New York | Dna probe for the identification of haemophilus influenzae |
| US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| MC2178A1 (fr) * | 1988-12-16 | 1992-05-22 | Nederlanden Staat | Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| NZ239643A (en) * | 1990-09-17 | 1996-05-28 | North American Vaccine Inc | Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group. |
| CA2059692C (en) * | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| US6592876B1 (en) | 1993-04-20 | 2003-07-15 | Uab Research Foundation | Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products |
| US5476929A (en) | 1991-02-15 | 1995-12-19 | Uab Research Foundation | Structural gene of pneumococcal protein |
| US5552146A (en) | 1991-08-15 | 1996-09-03 | Board Of Regents, The University Of Texas System | Methods and compositions relating to useful antigens of Moraxella catarrhalis |
| CA2138997C (en) | 1992-06-25 | 2003-06-03 | Jean-Paul Prieels | Vaccine composition containing adjuvants |
| EP0618813B1 (en) * | 1992-09-16 | 2002-01-09 | The University Of Tennessee Research Corporation | Antigen of hybrid m protein and carrier for group a streptococcal vaccine |
| SG48309A1 (en) | 1993-03-23 | 1998-04-17 | Smithkline Beecham Biolog | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
| ES2185658T3 (es) | 1993-05-18 | 2003-05-01 | Univ Ohio State Res Found | Vacuna para la otitis media. |
| ES2210262T3 (es) | 1993-09-22 | 2004-07-01 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Procedimiento que permite activar un glucido soluble con la ayuda de nuevos reactivos cianilantes para producir estructuras inmunogenas. |
| GB9326253D0 (en) * | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US5866135A (en) * | 1994-04-21 | 1999-02-02 | North American Vaccine, Inc. | Group A streptococcal polysaccharide immunogenic compositions and methods |
| WO1996002555A1 (en) | 1994-07-15 | 1996-02-01 | The University Of Iowa Research Foundation | Immunomodulatory oligonucleotides |
| US5565204A (en) * | 1994-08-24 | 1996-10-15 | American Cyanamid Company | Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections |
| US5681570A (en) * | 1995-01-12 | 1997-10-28 | Connaught Laboratories Limited | Immunogenic conjugate molecules |
| WO1996032963A1 (en) * | 1995-04-17 | 1996-10-24 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins |
| UA56132C2 (uk) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6440425B1 (en) | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
| US5843464A (en) | 1995-06-02 | 1998-12-01 | The Ohio State University | Synthetic chimeric fimbrin peptides |
| US5736533A (en) * | 1995-06-07 | 1998-04-07 | Neose Technologies, Inc. | Bacterial inhibition with an oligosaccharide compound |
| AU700080B2 (en) | 1995-06-07 | 1998-12-17 | Biochem Vaccines Inc. | Streptococcal heat shock proteins members of the HSP70 family |
| NZ311000A (en) | 1995-06-07 | 1999-04-29 | Smithkline Beecham Biolog | Vaccine comprising a polysaccharide antigen-carrier protein conjugate and a free carrier protein |
| GB9513074D0 (en) | 1995-06-27 | 1995-08-30 | Cortecs Ltd | Novel anigen |
| US6290970B1 (en) | 1995-10-11 | 2001-09-18 | Aventis Pasteur Limited | Transferrin receptor protein of Moraxella |
| US6090576A (en) | 1996-03-08 | 2000-07-18 | Connaught Laboratories Limited | DNA encoding a transferrin receptor of Moraxella |
| SE9601158D0 (sv) | 1996-03-26 | 1996-03-26 | Stefan Svenson | Method of producing immunogenic products and vaccines |
| EP0912608B1 (en) | 1996-05-01 | 2006-04-19 | The Rockefeller University | Choline binding proteins for anti-pneumococcal vaccines |
| US6245335B1 (en) * | 1996-05-01 | 2001-06-12 | The Rockefeller University | Choline binding proteins for anti-pneumococcal vaccines |
| US7341727B1 (en) | 1996-05-03 | 2008-03-11 | Emergent Product Development Gaithersburg Inc. | M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same |
| JPH102001A (ja) * | 1996-06-15 | 1998-01-06 | Okajima Kogyo Kk | グレーチング |
| US5882871A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | Saliva binding protein |
| US5882896A (en) | 1996-09-24 | 1999-03-16 | Smithkline Beecham Corporation | M protein |
| FR2763244B1 (fr) * | 1997-05-14 | 2003-08-01 | Pasteur Merieux Serums Vacc | Composition vaccinale multivalente a porteur mixte |
| JP2001502925A (ja) | 1997-06-03 | 2001-03-06 | コノート ラボラトリーズ リミテッド | モラクセラのラクトフェリン受容体遺伝子 |
| AU740956B2 (en) | 1997-07-21 | 2001-11-15 | Baxter Healthcare Sa | Modified immunogenic pneumolysin compositions as vaccines |
| US6224880B1 (en) * | 1997-09-24 | 2001-05-01 | Merck & Co., Inc. | Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines |
| US20050031638A1 (en) * | 1997-12-24 | 2005-02-10 | Smithkline Beecham Biologicals S.A. | Vaccine |
| GB9727262D0 (en) * | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
| US6709658B1 (en) * | 1998-02-12 | 2004-03-23 | Wyeth Holdings Corporation | Pneumococcal vaccines formulated with interleukin-12 |
| EP1067962B1 (en) | 1998-04-07 | 2010-03-24 | MedImmune, LLC | Derivatives of pneumococcal choline binding proteins for vaccines |
| GB9812613D0 (en) | 1998-06-11 | 1998-08-12 | Smithkline Beecham Biolog | Vaccine |
| CN1263510C (zh) | 1998-08-19 | 2006-07-12 | 巴克斯特健康护理股份有限公司 | 多糖－蛋白质缀合物或寡糖－蛋白质缀合物、其制备方法及其应用 |
| DE69940439D1 (de) * | 1998-12-21 | 2009-04-02 | Medimmune Inc | Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe |
| JP2002539273A (ja) * | 1999-03-19 | 2002-11-19 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
| GB9909077D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
| GB0022742D0 (en) * | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| CN201252175Y (zh) * | 2008-08-04 | 2009-06-03 | 富士康(昆山)电脑接插件有限公司 | 线缆连接器组件 |
-
2000
- 2000-03-17 JP JP2000606262A patent/JP2002539273A/ja active Pending
- 2000-03-17 SI SI200030988T patent/SI1163000T1/sl unknown
- 2000-03-17 AR ARP000101196A patent/AR022965A1/es not_active Application Discontinuation
- 2000-03-17 HK HK02103797.7A patent/HK1043730A1/zh unknown
- 2000-03-17 ES ES00910868T patent/ES2339737T3/es not_active Expired - Lifetime
- 2000-03-17 AR ARP000101195A patent/AR022964A1/es unknown
- 2000-03-17 DE DE60038166T patent/DE60038166T2/de not_active Expired - Lifetime
- 2000-03-17 TW TW089104977A patent/TWI281403B/zh not_active IP Right Cessation
- 2000-03-17 AT AT00910868T patent/ATE459373T1/de not_active IP Right Cessation
- 2000-03-17 WO PCT/EP2000/002467 patent/WO2000056359A2/en not_active Ceased
- 2000-03-17 KR KR1020017011948A patent/KR20020000785A/ko not_active Withdrawn
- 2000-03-17 AT AT00912626T patent/ATE387214T1/de active
- 2000-03-17 IL IL14504400A patent/IL145044A0/xx active IP Right Grant
- 2000-03-17 BR BR0009154-5A patent/BR0009154A/pt not_active IP Right Cessation
- 2000-03-17 PT PT00916983T patent/PT1162999E/pt unknown
- 2000-03-17 TR TR2001/02736T patent/TR200102736T2/xx unknown
- 2000-03-17 IL IL14504500A patent/IL145045A0/xx unknown
- 2000-03-17 EP EP10180520A patent/EP2277535A3/en not_active Ceased
- 2000-03-17 SI SI200030925T patent/SI1162999T1/sl unknown
- 2000-03-17 TW TW089104976A patent/TWI235064B/zh not_active IP Right Cessation
- 2000-03-17 TW TW089104978A patent/TWI286938B/zh not_active IP Right Cessation
- 2000-03-17 AR ARP000101194A patent/AR022963A1/es not_active Application Discontinuation
- 2000-03-17 HU HU0200367A patent/HU229968B1/hu active Protection Beyond IP Right Term
- 2000-03-17 MY MYPI20001047A patent/MY125387A/en unknown
- 2000-03-17 CA CA2366314A patent/CA2366314C/en not_active Expired - Lifetime
- 2000-03-17 KR KR1020017011939A patent/KR100798212B1/ko not_active Expired - Fee Related
- 2000-03-17 PL PL355180A patent/PL204890B1/pl unknown
- 2000-03-17 IL IL14504300A patent/IL145043A0/xx active IP Right Grant
- 2000-03-17 AU AU34307/00A patent/AU750913B2/en not_active Expired
- 2000-03-17 PL PL355264A patent/PL203917B1/pl unknown
- 2000-03-17 DK DK00916983T patent/DK1162999T3/da active
- 2000-03-17 EP EP00910868A patent/EP1162998B1/en not_active Expired - Lifetime
- 2000-03-17 DE DE60043930T patent/DE60043930D1/de not_active Expired - Lifetime
- 2000-03-17 CZ CZ20013378A patent/CZ20013378A3/cs unknown
- 2000-03-17 MX MXPA01009452A patent/MXPA01009452A/es not_active Application Discontinuation
- 2000-03-17 ES ES00916983T patent/ES2275499T3/es not_active Expired - Lifetime
- 2000-03-17 HK HK02103795.9A patent/HK1043728B/en not_active IP Right Cessation
- 2000-03-17 KR KR1020017011941A patent/KR100642044B1/ko not_active Expired - Fee Related
- 2000-03-17 EP EP00916983A patent/EP1162999B1/en not_active Expired - Lifetime
- 2000-03-17 EP EP07119247A patent/EP1880735A3/en not_active Withdrawn
- 2000-03-17 AU AU32919/00A patent/AU750788B2/en not_active Ceased
- 2000-03-17 PT PT00912626T patent/PT1163000E/pt unknown
- 2000-03-17 TR TR2001/02739T patent/TR200102739T2/xx unknown
- 2000-03-17 HK HK02103814.6A patent/HK1043731B/en not_active IP Right Cessation
- 2000-03-17 DE DE122009000054C patent/DE122009000054I1/de active Pending
- 2000-03-17 JP JP2000606264A patent/JP4846906B2/ja not_active Expired - Lifetime
- 2000-03-17 BR BR0009163-4A patent/BR0009163A/pt not_active IP Right Cessation
- 2000-03-17 DK DK00912626T patent/DK1163000T3/da active
- 2000-03-17 AT AT00916983T patent/ATE346608T1/de active
- 2000-03-17 NZ NZ513841A patent/NZ513841A/en not_active IP Right Cessation
- 2000-03-17 WO PCT/EP2000/002465 patent/WO2000056358A2/en not_active Ceased
- 2000-03-17 BR BR0009166-9A patent/BR0009166A/pt not_active Application Discontinuation
- 2000-03-17 WO PCT/EP2000/002468 patent/WO2000056360A2/en not_active Ceased
- 2000-03-17 AU AU38136/00A patent/AU750762B2/en not_active Ceased
- 2000-03-17 MY MYPI20001077A patent/MY125202A/en unknown
- 2000-03-17 ES ES00912626T patent/ES2300255T3/es not_active Expired - Lifetime
- 2000-03-17 NZ NZ513840A patent/NZ513840A/xx not_active IP Right Cessation
- 2000-03-17 BR BRPI0009163A patent/BRPI0009163B8/pt unknown
- 2000-03-17 HU HU0200373A patent/HU228499B1/hu not_active IP Right Cessation
- 2000-03-17 TR TR2001/02735T patent/TR200102735T2/xx unknown
- 2000-03-17 HU HU0200664A patent/HUP0200664A2/hu unknown
- 2000-03-17 PL PL00355178A patent/PL355178A1/xx not_active Application Discontinuation
- 2000-03-17 EP EP06124454A patent/EP1776962A1/en not_active Ceased
- 2000-03-17 CZ CZ20013380A patent/CZ303653B6/cs not_active IP Right Cessation
- 2000-03-17 DE DE60032120T patent/DE60032120T2/de not_active Expired - Lifetime
- 2000-03-17 CN CNB00807528XA patent/CN1192798C/zh not_active Expired - Lifetime
- 2000-03-17 JP JP2000606263A patent/JP2002540074A/ja not_active Withdrawn
- 2000-03-17 CZ CZ20013379A patent/CZ301445B6/cs not_active IP Right Cessation
- 2000-03-17 CN CNB008077738A patent/CN100339130C/zh not_active Expired - Fee Related
- 2000-03-17 CA CA002365296A patent/CA2365296A1/en not_active Abandoned
- 2000-03-17 EP EP00912626A patent/EP1163000B1/en not_active Expired - Lifetime
- 2000-03-17 CA CA002366152A patent/CA2366152A1/en not_active Abandoned
- 2000-03-17 CN CNB008077592A patent/CN1191852C/zh not_active Expired - Fee Related
-
2001
- 2001-03-17 NZ NZ513842A patent/NZ513842A/en unknown
- 2001-08-22 IL IL145044A patent/IL145044A/en not_active IP Right Cessation
- 2001-08-22 IL IL145043A patent/IL145043A/en not_active IP Right Cessation
- 2001-09-05 NO NO20014323A patent/NO330532B1/no not_active IP Right Cessation
- 2001-09-05 NO NO20014322A patent/NO20014322L/no not_active Application Discontinuation
- 2001-09-05 NO NO20014325A patent/NO330736B1/no not_active IP Right Cessation
-
2002
- 2002-08-26 US US10/228,666 patent/US20030147922A1/en not_active Abandoned
-
2004
- 2004-08-27 US US10/929,042 patent/US20050031646A1/en not_active Abandoned
-
2005
- 2005-08-31 US US11/216,226 patent/US20060002961A1/en not_active Abandoned
- 2005-09-30 US US11/240,193 patent/US20060093626A1/en not_active Abandoned
-
2007
- 2007-02-21 CY CY20071100247T patent/CY1107561T1/el unknown
-
2008
- 2008-04-10 CY CY20081100394T patent/CY1107390T1/el unknown
-
2009
- 2009-09-24 CY CY2009014C patent/CY2009014I1/el unknown
- 2009-09-24 BE BE2009C043C patent/BE1025464I2/fr unknown
- 2009-09-24 NL NL300415C patent/NL300415I1/nl unknown
- 2009-11-05 US US12/612,988 patent/US8926985B2/en not_active Expired - Lifetime
-
2010
- 2010-02-11 LU LU91652C patent/LU91652I2/fr unknown
- 2010-02-16 FR FR10C0008C patent/FR10C0008I2/fr active Active
- 2010-06-03 US US12/793,408 patent/US20100291138A1/en not_active Abandoned
- 2010-12-21 US US12/973,899 patent/US20110217329A1/en not_active Abandoned
- 2010-12-24 JP JP2010288197A patent/JP5551579B2/ja not_active Expired - Fee Related
-
2011
- 2011-08-30 NO NO2011014C patent/NO2011014I1/no unknown
-
2014
- 2014-11-21 US US14/550,345 patent/US9168313B2/en not_active Expired - Fee Related
-
2015
- 2015-07-14 HU HUS1500040C patent/HUS1500040I1/hu unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8926985B2 (en) | Vaccine | |
| ZA200107638B (en) | Vaccine. | |
| US20150079129A1 (en) | Vaccine | |
| HK1114012A (en) | Vaccine | |
| HK1106137A (en) | Vaccine against streptococcus pneumoniae | |
| MXPA01009455A (en) | Vaccine | |
| MXPA01009459A (es) | Vacuna |